Joachim Klosterkötter1. 1. Klinik für Psychiatrie und Psychotherapie, Universität zu Köln, Kerpener Strasse 62, Köln, Germany. joachim.klosterkoetter@uk-koeln.de
Abstract
INTRODUCTION: Despite recent advances in their treatment, schizophrenic disorders are still among the diseases that most severely impair patients' quality of life. For this reason, centers for the early recognition of schizophrenic disorders have come into existence worldwide. In these centers, much effort is devoted to the development and testing of suitable preventive strategies. METHODS: In this article, we selectively review the literature on the currently available means of assessing the individual risk of becoming ill with schizophrenia and of preventing the imminent onset of the disease. RESULTS: The currently recognized neurobiological and psychosocial risk factors are not predictive enough to enable the development and application of selective prevention measures for asymptomatic persons at risk. The imminent onset of schizophrenia can be predicted with high accuracy, however, in cases where an initially non-psychotic patient develops early cognitive symptoms that imply a risk of schizophrenia and then, later on in the prodrome of the disease (which typically lasts about five years), goes on to develop high-risk symptoms with mild psychosis. At this point, a differential strategy of indicated prevention can be put into action, including cognitive behavioral therapy, atypical antipsychotics in low doses, and neuroprotective agents. DISCUSSION: The current state of knowledge in this innovative field of research leads us to expect that it will soon be possible to offer individually tailored preventive measures to persons seeking medical help and advice because of the early warning signs of schizophrenia.
INTRODUCTION: Despite recent advances in their treatment, schizophrenic disorders are still among the diseases that most severely impair patients' quality of life. For this reason, centers for the early recognition of schizophrenic disorders have come into existence worldwide. In these centers, much effort is devoted to the development and testing of suitable preventive strategies. METHODS: In this article, we selectively review the literature on the currently available means of assessing the individual risk of becoming ill with schizophrenia and of preventing the imminent onset of the disease. RESULTS: The currently recognized neurobiological and psychosocial risk factors are not predictive enough to enable the development and application of selective prevention measures for asymptomatic persons at risk. The imminent onset of schizophrenia can be predicted with high accuracy, however, in cases where an initially non-psychoticpatient develops early cognitive symptoms that imply a risk of schizophrenia and then, later on in the prodrome of the disease (which typically lasts about five years), goes on to develop high-risk symptoms with mild psychosis. At this point, a differential strategy of indicated prevention can be put into action, including cognitive behavioral therapy, atypical antipsychotics in low doses, and neuroprotective agents. DISCUSSION: The current state of knowledge in this innovative field of research leads us to expect that it will soon be possible to offer individually tailored preventive measures to persons seeking medical help and advice because of the early warning signs of schizophrenia.
Entities:
Keywords:
early course; indicated prevention; risk factor; risk symptom; schizophrenia
Authors: Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Raimo K R Salokangas; Don Linszen; Max Birchwood; Georg Juckel; Anthony Morrison; José Luis Vázquèz-Barquero; Martin Hambrecht; Heinrich VON Reventlow Journal: World Psychiatry Date: 2005-10 Impact factor: 49.548
Authors: A R Yung; E Killackey; S E Hetrick; A G Parker; F Schultze-Lutter; J Klosterkoetter; R Purcell; P D Mcgorry Journal: Int Rev Psychiatry Date: 2007-12
Authors: Lisa J Phillips; Patrick D McGorry; Alison R Yung; Thomas H McGlashan; Barbara Cornblatt; Joachim Klosterkötter Journal: Br J Psychiatry Suppl Date: 2005-08
Authors: Andreas Bechdolf; Stephan Ruhrmann; Michael Wagner; Kai Uwe Kühn; Birgit Janssen; Ronald Bottlender; Anke Wieneke; Frauke Schulze-Lutter; Wolfgang Maier; Joachim Klosterkötter Journal: Br J Psychiatry Suppl Date: 2005-08
Authors: W Kissling; J Höffler; U Seemann; P Müller; E Rüther; U Trenckmann; A Uber; J M Graf von der Schulenburg; P Glaser; T Glaser; O Mast; D Schmidt Journal: Fortschr Neurol Psychiatr Date: 1999-01 Impact factor: 0.752
Authors: Heinz Häfner; Kurt Maurer; Stephan Ruhrmann; Andreas Bechdolf; Joachim Klosterkötter; Michael Wagner; Wolfgang Maier; Ronald Bottlender; Hans-Jürgen Möller; Wolfgang Gaebel; Wolfgang Wölwer Journal: Eur Arch Psychiatry Clin Neurosci Date: 2004-04 Impact factor: 5.270
Authors: Anthony P Morrison; Paul French; Lara Walford; Shôn W Lewis; Aoiffe Kilcommons; Joanne Green; Sophie Parker; Richard P Bentall Journal: Br J Psychiatry Date: 2004-10 Impact factor: 9.319
Authors: Patrick D McGorry; Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona Francey; Elizabeth M Cosgrave; Dominic Germano; Jenny Bravin; Tony McDonald; Alison Blair; Stephen Adlard; Henry Jackson Journal: Arch Gen Psychiatry Date: 2002-10